Alpha Cognition advanced its first full quarter of ZUNVEYL® commercialization in 2Q25, driving meaningful early adoption in the U.S. long-term care (LTC) market and securing a key regulatory milestone in China. By quarter-end, ZUNVEYL (benzgalantamine) had been ordered in over 300 LTC facilities across priority regions, with 65% placing repeat orders, signaling strong clinical confidence and operational fit. The sales team engaged more than 3,700 healthcare professionals, generating both new and repeat prescriptions. Clinician feedback continued to highlight ZUNVEYL’s cognitive and behavioral benefits alongside a favorable tolerability profile. The Company also secured its first national Medicare Part D contract with no prior authorization required, enhancing patient access ahead of schedule.